Ferguson Gemma N, Valant Celine, Horne James, Figler Heidi, Flynn Bernard L, Linden Joel, Chalmers David K, Sexton Patrick M, Christopoulos Arthur, Scammells Peter J
Medicinal Chemistry and Drug Action, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
J Med Chem. 2008 Oct 9;51(19):6165-72. doi: 10.1021/jm800557d. Epub 2008 Sep 5.
A pharmacophore-based screen identified 32 compounds including ethyl 5-amino-3-(4- tert-butylphenyl)-4-oxo-3,4-dihydrothieno[3,4- d]pyridazine-1-carboxylate ( 8) as a new allosteric modulator of the adenosine A1 receptor (A1AR). On the basis of this lead, various derivatives were prepared and evaluated for activity at the human A 1AR. A number of the test compounds allosterically stabilized agonist-receptor-G protein ternary complexes in dissociation kinetic assays, but were found to be more potent as antagonists in subsequent functional assays of ERK1/2 phosphorylation. Additional experiments on the most potent antagonist, 13b, investigating A1AR-mediated [(35)S]GTPgammaS binding and [(3)H]CCPA equilibrium binding confirmed its antagonistic mode of action and also identified inverse agonism. This study has thus identified a new class of A1AR antagonists that can also recognize the receptor's allosteric site with lower potency.
基于药效团的筛选鉴定出32种化合物,其中包括5-氨基-3-(4-叔丁基苯基)-4-氧代-3,4-二氢噻吩并[3,4-d]哒嗪-1-羧酸乙酯(8),它是一种新型腺苷A1受体(A1AR)变构调节剂。基于这一先导化合物,制备了各种衍生物,并对其在人A1AR上的活性进行了评估。在解离动力学试验中,许多受试化合物变构稳定了激动剂-受体-G蛋白三元复合物,但在随后的ERK1/2磷酸化功能试验中发现它们作为拮抗剂更有效。对最有效的拮抗剂13b进行的进一步实验,研究A1AR介导的[(35)S]GTPγS结合和[(3)H]CCPA平衡结合,证实了其拮抗作用模式,并确定了反向激动作用。因此,本研究鉴定出了一类新的A1AR拮抗剂,它们也能以较低的效力识别受体的变构位点。